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Abstract The bioactivity of interleukin-6 (IL-6) was found to be
dramatically reduced in fluids from sites of inflammation. Here,
we provide evidence that the neutrophil-derived serine proteases
elastase, proteinase 3 and cathepsin G are mainly involved in its
degradation and subsequent inactivation. The initially hydrolyzed
peptide bonds were detected to be Val11-Ala12 and Leu19-Thr20
(elastase), Phe78-Asn79 (cathepsin G) and Ala145-Ser146 (pro-
teinase 3). The soluble IL-6 receptor elicits a protective effect
against the IL-6 inactivation by cathepsin G only. The
inactivation of IL-6 by neutrophil-derived serine proteases might
act as a feedback mechanism terminating the IL-6-induced
activation of neutrophils.
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1. Introduction
The pleiotropic cytokine interleukin-6 (IL-6) plays a major
role in the regulation of acute in£ammation by eliciting both,
proin£ammatory and anti-in£ammatory e¡ects [1,2]. IL-6 is
involved in the activation of unspeci¢c immune defense reac-
tions and is necessary for the antigen speci¢c immune re-
sponse [1,2]. It is reported that IL-6 is also a key cytokine
for the limitation and resolution of the in£ammatory process:
In contrast to the classic proin£ammatory cytokines, IL-1 and
TNF-K, IL-6 induces the release of several anti-in£ammatory
factors [2,3]. However, these wide spreading and apparently
paradoxical e¡ects of IL-6 are integrated in a complex net-
work of cytokines and other in£ammatory mediators. The IL-
6 bioactivity is controlled by cell surface bound and soluble
receptors, other binding proteins and probably by di¡erent
tissue speci¢c posttranslational modi¢cations [4,5].
High IL-6 concentrations are detectable in the very early
phase of in£ammation, mainly released by endothelial cells,
monocytes and neutrophils [6^10]. At local sites of in£amma-
tion we found excessively elevated IL-6 concentrations [8]. By
comparative measurements of IL-6 concentrations and bioac-
tivities, a discrepancy between high immunochemically detect-
able concentrations of IL-6 and its bioactivity became evident.
Since at sites of in£ammation high amounts of active pro-
teolytic enzymes are released by invading neutrophils in close
temporal correlation to the elevated IL-6 concentrations [8],
this study focused on the e¡ect of these enzymes on the bio-
logical activity and molecular integrity of IL-6. The conse-
quences of the proteolytical IL-6 inactivation for local in£am-
matory processes and the relevance of these ¢ndings with
respect to the measurement of IL-6 concentrations in in£am-
matory exudates will be discussed.
2. Materials and methods
2.1. Patient samples
In£ammatory exudates were obtained from patients with acute in-
£ammatory diseases as approved by the local Ethics Committee.
Synovial £uids, obtained from patients with arthritis by arthrocentesis
(knee) for diagnostic purposes, were provided from the Clinic of
Rheumatology. Ascites and pleural e¡usions were obtained from pan-
creatitis patients during surgical treatments, CSF samples from neuro-
trauma patients via subdural drains established for monitoring and
minimizing intracranial pressure. Cell-free supernatants of the exu-
dates were prepared by a two-step centrifugation procedure (15 min,
700Ug ; 10 min, 900Ug) within 30 min after collection and stored at
380‡C until use.
2.2. Determination of IL-6 concentrations and bioactivities
IL-6 concentrations in exudates were detected by ELISA (R and D
Systems), IL-6 bioactivities assayed by determining the proliferation
rate of IL-6 sensitive B9 hybridoma cells (ATCC). In both assays
puri¢ed human lymphocyte-derived IL-6 (Boehringer Mannheim), ad-
justed to the international IL-6 standard (NIBSC), was used as a
standard.
2.3. Inactivation of IL-6 by neutrophils and puri¢ed neutrophil-derived
proteases
Isolated neutrophil granulocytes (puritys 98%, viability 95^99%) as
well as lysates and subcellular fractions of these cells were prepared as
previously described [8,11]. E¡ects of vital neutrophils on the molec-
ular integrity and bioactivity of IL-6 were proven by incubating 1 Wg
of carrier-free, rh IL-6 in the presence of 107 cells/ml serum-free
DMEM. After various incubation periods, cells were removed by
passing 100 Wl-sample aliquots through 0.22 Wm Filters (Millipore).
Additionally, rhIL-6 was incubated with lysates and subcellular frac-
tions of neutrophils or puri¢ed active elastase (NE), cathepsin G (Cat
G) from ICN or proteinase 3 (PR 3) from IBL. Hydrolysis was
stopped by adding a protease inhibitor mixture (IL-6 bioactivity
measurements) or by immediate heating to 100‡C in reducing sample
bu¡er. IL-6 proteolysis products were analyzed by SDS-PAGE under
reducing conditions (MiniProtean II, Bio-Rad), followed by silver
staining or Western blotting using an a⁄nity puri¢ed, polyclonal
anti-human IL-6 rabbit IgG as ¢rst antibody and chromogenic or
chemoluminescence detection systems.
2.4. Cleavage site analysis by N-terminal peptide sequencing and
MALDI-TOF
The N-terminal sequencing of IL-6 cleavage products was per-
formed by Edman-degradation (ABI Procise system). Additionally,
cleavage sites were identi¢ed by MALDI-TOF mass spectrometry.
Proteolytical degradation was performed with 0.2 Wg/Wl carrier-free,
unglycosylated rh IL-6 in 40 mM Tris-bu¡er plus a ¢nal protease
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concentration of 0.01 Wg/Wl and stopped by adding 2P,5Pdihydroxy
acetophenon (Matrix, pH = 3.5). Mass spectra were obtained by using
a Hewlett-Packard G2025A LD-TOF system, calibrated externally by
Hewlett-Packard mass standards. The sequences of IL-6 fragments
were predicted using the General Protein Mass Analysis for Windows
2.13 software.
3. Results
3.1. Discrepancy between biological activity and
immunochemically detectable concentrations of IL-6 in
in£ammatory exudates
In various biological £uids derived from sites of acute in-
£ammation, such as CSF, ascites, pleural e¡usions and syno-
vial £uids, excessively elevated IL-6 concentrations (up to
60129 IU/ml) are detectable by ELISA. Since the high pro-
teolytic potential at sites of in£ammation might have consid-
erable in£uence on the bioactivity of cytokines, we measured
the bioactivity of IL-6 in comparison to the immunochemi-
cally detectable values.
For standardization and direct comparability of the results
obtained by bioassay and ELISA, aliquots of an identical IL-6
standard preparation, adjusted to the international IL-6
standard, were used. Comparing the corresponding IL-6 val-
ues obtained by ELISA or bioassay, a signi¢cant discrepancy
in the vast majority of in£ammatory exudates became evi-
dent: Taken together, in about 76% of all examined in£am-
matory exudates (n = 115) the IL-6 bioactivity was consider-
ably below the predicted value. In Table 1, the results of the
comparing IL-6 measurements for each kind of the in£amma-
tory exudates, are presented separately. In Fig. 1 the individ-
ual values of the immunochemically detected IL-6 concentra-
tions versus the hybridoma growth promoting activities are
given.
3.2. Proteolytical degradation of IL-6 in the presence of vital
neutrophils, neutrophil lysates and supernatants of
activated neutrophils
Since in in£ammatory exudates high amounts of activated
neutrophils (up to 98U106 cells/ml) as well as high concen-
trations and activities of neutrophil proteases (up to 40 Wg/ml)
were detectable [8], we focused our interest on the e¡ects of
activated neutrophils on the molecular integrity and biological
activity of IL-6 in vitro. Puri¢ed, glycosylated rh IL-6 was
exposed to 107 vital, activated neutrophils, which release ac-
tive proteases by degranulation and bear several endoproteo-
lytic enzymes on the plasma membrane. Western blot analysis
using a polyclonal a⁄nity puri¢ed anti-IL-6 antibody revealed
a rapid cleavage of IL-6 into immunoreactive fragments with
an molecular weight below 14 kDa (Fig. 2, lane 2). Incubation
for 120 min led to a further hydrolysis of these fragments
(Fig. 2, lane 3). Among several group speci¢c protease inhib-
itors only the serine protease inhibitor diisopropyl £uorophos-
phate (DFP) prevented the IL-6 cleavage almost completely
(Fig. 2, lanes 4 and 5). In contrast, the IL-6 degradation was
not blocked in the presence of metalloproteinase inhibitors
(Fig. 2, lane 5).
To get further information, on which proteases are involved
in the IL-6 cleavage, rh IL-6 was incubated with lysates and
subcellular fractions of activated neutrophils. The exposure of
IL-6 to neutrophil lysates resulted in a rapid cleavage of IL-6
too (Fig. 3, lane 5). This was inhibited by DFP (Fig. 3, lane
6), whereas the metalloproteinase inhibitors EDTA plus or-
tho-phenanthroline (lane 7) or the cysteine protease inhibitor
E-64 elicited only slight e¡ects (lane 8). Analyzing the IL-6
cleavage by various subcellular fractions, a remarkable IL-6
cleavage was observable in the presence of the granule and
membrane fraction (Fig. 3, lanes 2 and 3) only.
3.3. Cleavage of IL-6 by puri¢ed neutrophil-derived serine
proteases
The fact that most of the IL-6-degrading activity is inhib-
itable by DFP and is localized in the granule and membrane
Table 1
IL-6 bioactivity versus immunochemically detected IL-6 concentrations, summarized for each kind of in£ammatory exudate, separately
n IL-6 (IU/ml) mean þ S.E.M. relative amount of samples with IL-6 bioactivity
lower than predicted as predicted higher than predicted
Ascites 17 7167 þ 2500 76.5% 23.5% 0%
Synovial £uids 20 1987 þ 345 40% 50% 10%
Pleural e¡usions 13 6568 þ 2184 92.3% 7.6% 0%
Drained CSF 65 5665 þ 1406 84.6% 13.9% 1.5%
Summary 115 5349 þ 917 76.5% 20.9% 2.6%
The intra- and interassay deviations of IL-6 measurements by ELISA or bioassay (approved with citrated plasma, CSF and medium spiked
with natural IL-6) did not exceed values of 9.8% and 22%, respectively. Based on these results, bioactivity values with more than 25% deviation
from the predictions based on ELISA data were considered to be signi¢cantly reduced (or elevated).
Fig. 1. Immunochemically detected IL-6 concentrations versus the
hybridoma growth promoting activities in in£ammatory exudates
from local sites of in£ammation. The concentrations of IL-6 in
CSF, ascites, pleural e¡usions and synovial £uids were measured by
ELISA, the bioactivities determined using the B9 hybridoma growth
assay. The data calculated on the basis of the international IL-6
standard are given in IU/ml.
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fraction of neutrophils, suggested a crucial role of serine pro-
teases derived from the granules of neutrophils in the proteol-
ysis of IL-6. Because of their enzymatic features the serine
proteases NE, PR 3 and Cat G from the azurophilic granules
are main candidates for an involvement in the IL-6 fragmen-
tation. Therefore, the capacity of each of the proteases to
catalyze the cleavage and inactivation of IL-6 was analyzed.
The incubation of rh IL-6 with puri¢ed NE, PR 3 or Cat G
under serum-free conditions resulted in a time-dependent loss
of its bioactivity. No signi¢cant di¡erence between the inacti-
vation kinetics of unglycosylated or glycosylated rh IL-6 was
observable (Fig. 4).
Western blot analysis revealed that the hydrolysis of rh IL-6
catalyzed by NE initially led to the formation of two inter-
mediate, immunochemically detectable fragments (Fig. 5A,
lane 4 and 5). By mass spectrometry, the molecular weights
of the fragments of unglycosylated rh IL-6 were determined to
be 19 770 kDa and 18 906 kDa. The N-terminal sequences
AAPHR and TSSERI of these fragments indicate that pep-
tides of 11 or 19 amino acids are released from the N-terminus
of the IL-6 molecule, respectively. Both, the Val11-Ala12 and
the Leu19-Thr20 cleavage sites, are in excellent agreement with
the results of mass analysis and sequence based calculations.
During longer incubation periods, both fragments disap-
peared progressively. In silver stained gels as well as by
mass spectrometry a further stepwise degradation of IL-6
into small peptides via 16.2 kDa, 15.1 kDa and 12.8 kDa
fragments was observed.
PR 3 initially releases an immunoreactive 16.2 kDa frag-
ment from unglycosylated rh IL-6 (Fig. 5A, lanes 2 and 3),
but was not as potent as NE or Cat G. The N-terminal se-
quence of this fragment corresponds to the N-terminus of
intact IL-6. By mass spectrometry the Ala145-Ser146 peptide
bond was identi¢ed as initial cleavage site. Cat G initially
catalyzes the hydrolysis of unglycosylated IL-6 into two frag-
ments with apparent molecular weights of 9 and 12 kDa. Only
Fig. 2. Western blot analysis after exposure of IL-6 to vital acti-
vated neutrophils. 1 Wg rh glycosylated IL-6 was incubated in the
presence of 107 vital activated neutrophils under serum-free condi-
tions. After the indicated time points, sample aliquots were applied
to a 15% SDS-PAGE gel, run under reducing conditions and blot-
ted on nitrocellulose membrane. IL-6 and fragments were detected
using an a⁄nity-puri¢ed, polyclonal anti-IL-6 IgG as primary anti-
body. The positions of molecular weight standards are given at the
edge of the panel.
Fig. 3. Hydrolysis of IL-6 by subcellular fractions and lysates of
neutrophils. Glycosylated rh IL-6 (0.25 Wg per lane) was incubated
for 30 min with 10 Wl of subcellular fraction extracts or a lysate of
5U108 freshly isolated neutrophils. Group speci¢c inhibitors were
added as indicated. The degradation of IL-6 was analyzed by SDS-
PAGE and Western blotting. The positions of molecular weight
standards are given at the edge of the panel.
Fig. 4. In£uence of NE, Cat G or PR 3 on the bioactivity of ungly-
cosylated IL-6 (A) or glycosylated IL-6 (B). Both forms of rh IL-6
were incubated with puri¢ed NE, Cat G or PR 3 for 15, 30 and 60
min. The hybridoma growth promoting activity of IL-6 after the
protease treatment was determined in triplicates. The results are giv-
en as percentage of the initial bioactivity of the untreated control
IL-6.
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the 12 kDa fragment was capable of binding the polyclonal
anti-IL-6 antibody (Fig. 5A, lanes 6 and 7). Mass spectrom-
etry and the N-terminal sequencing revealed that these frag-
ments were released by hydrolyzing the Phe78-Asn79 bond.
In vivo, IL-6 was found to form complexes with the soluble
form of the ligand-binding IL-6 receptor subunit gp 80 (sIL-
6R) and the soluble form of the signal-transducing receptor
subunit gp 130 (sgp130). The aim of further investigations was
to evaluate the in£uence of sIL-6R on the degradation of its
ligand IL-6 by NE, PR 3 and Cat G. (Fig. 5, part B). The
Western blot shows that only the cleavage of IL-6 by Cat G
was almost completely abolished in the presence of the sIL-6R
(lane 9, control in lane 8).
3.4. Inactivation of IL-6 by protease-rich in£ammatory
exudates
By Western blotting of 11 in£ammatory CSF-samples with
excessive high IL-6 concentrations (s 100 ng/ml), very weak
immunoreactive protein bands with an apparent molecular
weight of approximately 10 kDa were detectable. Since these
results allowed no clear conclusion about the formation of IL-
6 fragments in vivo, the capacity of selected in£ammatory
exudates to inactivate exogenously added rh IL-6 and the
in£uence of various group speci¢c protease inhibitors was in-
vestigated. As demonstrated in Fig. 6, glycosylated IL-6 is
degraded by a protease-rich CSF or a pleural e¡usion sample.
In both cases, IL-6 fragments (molecular weights 21.5 kDa)
are detectable by Western blotting after 2 or 6 h of incuba-
tion. The IL-6 degradation by proteases in these samples was
abolished by DFP only (lanes 4 and 8). By comparing the
fragment pattern in this experiments with those generated
by each of the puri¢ed enzymes (Fig. 5, part A), fragments
comparable with the NE or PR 3 generated proteolysis prod-
ucts were found.
4. Discussion
In this report, we show that in in£ammatory exudates the
bioactivity of IL-6 is often considerably below the predicted
level based on the immunochemically detected concentration.
Since at sites of in£ammation high amounts of active pro-
teases are released, especially by invading neutrophils in tem-
poral correlation to elevated IL-6 concentrations, an in£uence
of these enzymes on the molecular integrity and bioactivity of
IL-6 is highly probable. Other conceivable causes for a re-
duced IL-6 bioactivity in these samples, as e.g. the presence
of immunosuppressive drugs or anti-IL-6 auto-antibodies,
which may a¡ect the accuracy of IL-6 detection systems
[12,13], could be virtually excluded.
Indeed, our results provide evidence that NE, PR 3 and Cat
G play a crucial role in the inactivation of IL-6 at sites of
in£ammation. Each of these proteases is capable of inactivat-
ing IL-6. Although the primary amino acid sequence of IL-6
contains numerous potential cleavage sites [14,15], each of the
proteases was found to catalyze preferentially the hydrolysis
of distinct peptide bonds within the intact IL-6 molecule, in-
dependently of its glycosylation status. Examinations of the
tertiary structure of the human IL-6 molecule (Brookhaven-
code 1IL6, RasMol-software) showed that the initially cleaved
peptide bonds are located outside the main four helical bundle
[16]. The peptide bonds, initially cleaved by NE, are located
within the free accessible N-terminal loop sequence. Since the
importance of this sequence region for the IL-6 bioactivity is
controversially discussed [17,18], we assume that the rapid loss
of bioactivity is a result of structural changes in other parts of
the molecule following the removal of the N-terminal loop
sequence.
PR 3 attacks initially the Ala145-Ser146 bond of the IL-6
molecule, which is located in a small helical region outside
the main four helical bundle and is thought to play a pivotal
role in the structural stabilization of the helix bundle [16].
Thus, it is probable that proteolysis within this region results
in drastic structural changes. Especially with respect to the
similar substrate speci¢cities of PR 3 and NE [19], it is inter-
esting that PR3 and NE cleave preferentially di¡erent peptide
Fig. 5. Hydrolysis of unglycosylated IL-6 by puri¢ed NE, Cat G or
PR 3 (A) and in£uence of sIL-6R on the IL-6 degradation (B). A:
Unglycosylated rh IL-6 (0.25Wg per lane) was incubated with 0.05 Wg
PR 3, NE and Cat G for 15 or 60 min, and subjected to Western
blot analysis using the polyclonal anti-IL-6 IgG as primary antibody
(control: lane 1). B: rh IL-6 preincubated in the presence or ab-
sence of a ¢ve-fold molar surplus of rh sIL-6R, was exposed to NE,
PR 3 or Cat G for 30 min. Western blot analysis was performed as
described in (A).
Fig. 6. Degradation of exogenously added IL-6 by proteases in in-
£ammatory exudates. Glycosylated rh IL-6 (0.25 Wg per lane, un-
treated control in lane 1) added to a CSF sample (lanes 2^5) or to
a prediluted pleural e¡usion sample (lanes 6^9) was incubated in the
absence or presence of serine or metalloproteinase inhibitors.
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bonds of the IL-6 molecule. This supports the idea that both
enzymes prefer di¡erent molecular interactions in extended
substrate binding sites.
The Phe78-Asn79 bond hydrolyzed initially in the presence
of Cat G, is located within the loop sequence connecting helix
A and B. The Phe in P1-position is in agreement with the
previously reported preference of Cat G for the catalyzation
of the hydrolysis of peptide bonds containing aromatic amino
acids [20]. The side chains of Phe78 and Asn79 are located
right next to the Met side chain of the C-terminus of IL-6.
Interactions between these side chains seem to be essential for
a stable C-terminal structure, which was described to play a
critical role for the IL-6 bioactivity [21]. This might explain
the loss of bioactivity following the cleavage of the Phe78-
Asn79 bond. Moreover, the Phe78 residue was described to
be involved in the IL-6 receptor binding [22]. This is in agree-
ment with our ¢ndings, that in the presence of sIL-6R the
cleavage of IL-6 by Cat G is almost completely prevented.
It is likely that the Phe78-Asn79 peptide bond is not accessible
in the IL-6/sIL-6R complex, supporting that sIL-6R functions
as a carrier for bioactive IL-6 by protecting it against proteo-
lytical degradation [23,24]. Possible e¡ects of the soluble
gp130 molecule, which e⁄ciently binds to IL-6/sIL-6R com-
plexes, on the proteolytical inactivation of IL-6 remain to be
elucidated.
The direct comparison of the immunoreactive IL-6 frag-
ment pattern found after the exposure of IL-6 to vital acti-
vated neutrophils with the pattern generated in the presence of
the single puri¢ed enzymes, suggests that in vivo IL-6 is in-
activated by synergistic action of di¡erent surface-bound and
soluble proteases. Unfortunately, we were not able to provide
a convincing detection of naturally occurring IL-6 fragments,
which allows comparisons to in vitro formed IL-6 fragments.
The concentrations of IL-6, and potentially formed fragments,
in the CSF samples are near the detection limit of the Western
blotting method and all engagements to concentrate or isolate
IL-6 fragment(s) were accompanied with a substantial loss of
immunoreactive protein. By proving the e¡ects of protease-
rich in£ammatory exudates on exogenously added rh IL-6, we
found fragments which correspond to those released in the
presence of puri¢ed NE and PR 3. However, this and the
results of the inhibitor studies supports that these proteases
play a pivotal role in the initiation of the IL-6 inactivation at
sites of in£ammation.
As mentioned above, there are hints that in vivo other
proteases from di¡erent cell types may be involved in the
further degradation of IL-6. Interestingly, it is likely that be-
sides host proteinases also bacterial proteases may process
cytokines in infected tissues: Recently, it has been shown
that proteases derived from Porphyromonas gingivalis in pe-
riodontal plaques are potent to inactivate IL-6 rapidly [25].
In the circulation IL-6 seems to be protected against the
rapid degradation by such enzymes, because protease inhibi-
tors as well as protective carrier proteins are available in much
higher concentrations than at sites of in£ammation (data not
shown).
Our data rise the question of the putative biological con-
sequences of the proteolytical inactivation of IL-6 at sites of
in£ammation. A number of reports demonstrated that espe-
cially neutrophil-derived proteases are important tools for the
regulation of the biological activity of in£ammation-related
cytokines [26^33]. Since IL-6 has been described to elicit
both, pro-in£ammatory and anti-in£ammatory e¡ects [1,2],
it is di⁄cult to assess whether the inactivation of IL-6 is
rather limiting or promoting the local in£ammatory process.
We and others could previously demonstrate that IL-6 induces
the release of serine proteases from azurophilic granules of
neutrophils [8,34,35]. Therefore, the inactivation of IL-6 by
the same enzymes might represent a direct negative feedback
mechanism with respect to IL-6 e¡ects on neutrophils. This is
in analogy to conclusions drawn in reports describing the
proteolytical inactivation of the neutrophil stimulating cyto-
kine TNF-K by neutrophil-derived enzymes [30,31]. A com-
bined inactivation of IL-6 and TNF-K was recently shown to
result in the prevention of the acute phase response [36]. Be-
yond that, neutrophil-derived serine proteases are reported to
be involved in the release of active IL-1L or TNF-K from the
membrane-bound precursors as well as to enhance the bioac-
tivity of IL-8 [32,37]. Interestingly, some fragments of cyto-
kines released by proteolysis were found to elicit new biolog-
ical activities [33,38,39]. A comparable relevance of
intermediate IL-6 fragments is conceivable, but in view of
the rapid further cleavage, doubtful.
Furthermore, the observed discrepancy between the immu-
noreactive levels and bioactivities of IL-6 in in£ammatory
exudates shows that it is impossible to draw direct conclusions
to the bioactivity of a cytokine from ELISA data. Partially-
degraded cytokines may be not detectable by bioassays or
may cause variable results of various ELISAs using di¡erent
antibodies for the cytokine detection. Consequently, our re-
sults emphasize that the handling of samples with a putative
high proteolytic potential requires improved, standardized
protocols.
In summary, the present study demonstrates that neutro-
phil-derived serine proteases play a crucial role in the regula-
tion of the biological potency of IL-6 at local sites of in£am-
mation. The proteolytical inactivation of stimulating
cytokines may act as feedback mechanism important for the
limitation and termination of immunostimulating signals.
Acknowledgements: We thank Dr. H.-U. Schulz (Clinic of Surgery),
Prof. Dr. J. Kekow (Clinic of Rheumatology) and Prof. Dr. H.-J.
Synowitz (Clinic of neurosurgery) for providing the in£ammatory
exudates and Mrs. I. Meinert for her excellent technical assistance.
References
[1] Hirano, T. (1998) Int. Rev. Immunol. 16, 249^284.
[2] Tilg, H., Dinarello, C.A. and Mier, J.W. (1997) Immunol. Today
18, 428^432.
[3] Zhou, D., Munster, A.M. and Winchurch, R.A. (1991) FASEB J.
5, 2582^2585.
[4] May, L.T., Santhanam, U., Tatter, S.B., Ghrayeb, J. and Sehgal,
P.B. (1989) Ann. N.Y. Acad. Sci. 557, 114^119.
[5] Sehgal, P.B. (1996) Proc. Soc. Exp. Biol. Med. 213, 238^247.
[6] Ohzato, H., Monden, M., Yoshizaki, K., Ogata, A., Nishimoto,
N., Gotoh, M., Kishimoto, T. and Mori, T. (1993) Biochem.
Biophys. Res. Commun. 197, 1556^1562.
[7] Padova, F.D., Pozzi, C., Tondre, M.J. and Tritapepe, R. (1991)
Clin. Exp. Immunol. 85, 137^142.
[8] Bank, U., Reinhold, D., Kunz, D., Schulz, H.-U., Schneemilch,
C., Brandt, W. and Ansorge, S. (1997) In£ammation 19, 83^99.
[9] Cicco, N.A., Lindemann, A., Content, J., Vandenbussche, P.,
Lu«bbert, M., Gauss, J., Mertelsmann, R. and Herrmann, F.
(1990) Blood 75, 2049^2052.
[10] Sironi, M., Breviario, F., Proserpio, P., Biondi, A., Vecchi, A.,
Van Damme, J., Dejana, E. and Mantovani, A. (1989) J. Immu-
nol. 142, 549^553.
FEBS 22900 11-11-99
U. Bank et al./FEBS Letters 461 (1999) 235^240 239
[11] Sengelov, H., Kjeldsen, L., Diamond, M.S., Springer, T.A. and
Borregaard, N. (1993) J. Clin. Invest. 92, 1467^1476.
[12] Barrera, P., Boerbooms, A.M., Sauerwein, R.W., Demacker,
P.N., Van de Putte, L.B. and Van der Meer, J.W. (1994) Lym-
phokine Cytokine Res. 13, 155^159.
[13] Bendtzen, K., Hansen, M.B., Ross, C. and Svenson, M.H. (1998)
Immunol. Today 19, 209^211.
[14] Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y.,
Matsuda, T., Kashiwamura, S., Nakajima, K., Koyama, K., Iwa-
matsu, A., Tsunasawa, S., Sakiyama, F., Matsui, H., Takahara,
Y., Taniguchi, T. and Kishimoto, T. (1986) Nature 324, 73^76.
[15] May, L.T., Helfgott, D.C. and Sehgal, P.B. (1986) Proc. Natl.
Acad. Sci. USA 83, 8957^8961.
[16] Somers, W., Stahl, M. and Seehra, J.S. (1997) EMBO J. 16, 989^
997.
[17] Breton, J., La Fiura, A., Bertolero, F., Orsini, G., Valsasina, B.,
Ziliotto, R., De Filippis, V., Polverino de Laureto, P. and Fon-
tana, A. (1995) Eur. J. Biochem. 227, 573^581.
[18] Brakenho¡, J.P., Hart, M., De Groot, E.R., Di Padova, F. and
Aarden, L.A. (1990) J. Immunol. 145, 561^586.
[19] Rao, N.V., Wehner, N.G., Marshall, B.C., Sturrock, A.B.,
Huecksteadt, T.P., Rao, G.V., Gray, B.H. and Hoidal, J.R.
(1991) Ann. N.Y. Acad. Sci. 624, 61^67.
[20] Salvesen, G.S. (1999) in: Handbook of Proteolytic Enzymes
(Barrett, A.J., Rawlings, N.D. and Woessner, J.F., Eds), chapter
16, Academic Press, New York.
[21] Lutticken, C., Kruttgen, A., Moller, C., Heinrich, P.C. and Rose-
John, S. (1991) FEBS Lett. 282, 265^267.
[22] Tonatti, C., Cabibbo, A., Sporena, E., Salvati, A., Cerretani, M.,
Sera¢ni, S., Lahm, A., Cortese, R. and Ciliberto, G. (1996)
EMBO J. 15, 2726^2737.
[23] Ehlers, M., Grotzinger, J., Fischer, M., Bos, H.K., Brakenho¡,
J.P. and Rose-John, S. (1996) J. Interferon Cytokine Res. 16,
569^576.
[24] Peters, M., Jacobs, S., Ehlers, M., Vollmer, P., Mullberg, J.,
Wolf, E., Brem, G., Meyer zum Bu«schenfelde, K.H. and Rose-
John, S. (1996) J. Exp. Med. 183, 1399^1406.
[25] Banbula, A., Bugno, M., Kuster, A., Heinrich, P.C., Travis, J.
and Potempa, J. (1999) Biochem. Biophys. Res. Commun. 261,
598^602.
[26] Baggiolini, M., Imboden, P. and Detmers, P. (1992) Cytokine 4,
1^17.
[27] Brandt, E., Van Damme, J. and Flad, H.-D. (1991) Cytokine 3,
311^321.
[28] Csernok, E., Szymkowiak, C.H., Mistry, N., Daha, M.R., Gross,
W.L. and Kekow, J. (1996) Clin. Exp. Immunol. 105, 104^111.
[29] Robache-Gallea, S., Morand, V., Bruneau, J.M., Schoot, M.,
Tagat, E., Realo, E., Chouaib, S. and Roman-Roman, S.
(1995) J. Biol. Chem. 270, 23688^23692.
[30] Scuderi, P., Nez, P.A., Duerr, M.L., Wong, B.J. and Valdez, M.
(1991) Cell. Immunol. 135, 299^313.
[31] Nortier, J., Vandenabeele, P., Noel, E., Bosseloir, Y., Goldman,
M. and Deschodt-Lanckman (1991) Life Sci. 49, 1879^1886.
[32] Padrines, M., Wolf, M., Walz, A. and Baggiolini, A. (1994)
FEBS Lett. 352, 231^235.
[33] Ariel, A., Yavin, E.J., Hershkoviz, R., Avron, A., Franitza, S.,
Hardan, I., Cahalon, L., Fridkin, M. and Lider, O. (1998)
J. Immunol. 161, 2465^2476.
[34] Borish, R., Rosenbaum, R., Albury, L. and Clark, S. (1989) Cell.
Immunol. 121, 280^289.
[35] Johnson, J.L., Moore, E.E., Tamura, D.Y., Zallen, G., Bi¥,
W.L. and Silliman, C.C. (1998) J. Surg. Res. 76, 91^94.
[36] Bopst, M., Hass, C., Car, B. and Eugster, H.P. (1998) Eur. J.
Immunol. 28, 4130^4137.
[37] Coeshott, C., Ohnemus, C., Pilyavskaya, A., Ross, S., Wieczorek,
M., Kroona, H., Leimer, A.H. and Cheronis, J. (1999) Proc.
Natl. Acad. Sci. USA 96, 6261^6266.
[38] Dinarello, C.A., Clowes Jr., G.H., Gordon, A.H., Saravis, C.A.
and Wol¡, S.M. (1984) J. Immunol. 133, 1332^1338.
[39] Obal, F., Opp, M. and Caby, A.B. (1990) Am. J. Physiol. 259,
439^446.
FEBS 22900 11-11-99
U. Bank et al./FEBS Letters 461 (1999) 235^240240
